MESOBLAST LIMITED - Announcements

0.00%

$2.29

Market Cap $2.931B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. LATEST: Race Oncology Accelerates Game-Changing Cancer Drug.

Announcements

Filter Results

All Price Sensitive Only

MSB	Notification of cessation of securities - MSB		16/10/23	22.14KB	Share
MSB	Notification regarding unquoted securities - MSB		16/10/23	25.52KB	Share
MSB	Final Director's Interest Notice		29/09/23	289.13KB	Share
MSB	Jane Bell Appointed Chair of Audit and Risk Committee		26/09/23	133KB	Share
MSB	Mesoblast Type A Meeting with FDA		21/09/23	180.71KB	Share
MSB	MSB Annual Financial Results and Operational Update	PRICE SENSITIVE	31/08/23	430.53KB	Share
MSB	Annual Financial Results Presentation		31/08/23	1.55MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	31/08/23	2.9MB	Share
MSB	Mesoblast 2023 Full Year Financial Results Webcast		29/08/23	113.86KB	Share
MSB	Change in substantial holding		29/08/23	982.31KB	Share
MSB	Ceasing to be a substantial holder		11/08/23	386.68KB	Share
MSB	Ceasing to be a substantial holder		10/08/23	382.31KB	Share
MSB	Change in substantial holding		10/08/23	477.4KB	Share
MSB	Change in substantial holding		09/08/23	463.15KB	Share
MSB	Change in substantial holding		09/08/23	481.52KB	Share
MSB	Update on BLA for Graft Versus Host Disease	PRICE SENSITIVE	04/08/23	178.56KB	Share
MSB	Change in substantial holding		03/08/23	560.83KB	Share
MSB	Trading Halt	PRICE SENSITIVE	02/08/23	195.14KB	Share
MSB	Change in substantial holding		01/08/23	538.92KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	401.67KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Ys		07/07/23	566.38KB	Share
MSB	Change of Director's Interest Notice		13/06/23	259.12KB	Share
MSB	Mesoblast Director Appointed to Strategic Advisory Role		05/06/23	161.1KB	Share
MSB	MSB Reports Q3 Financial Results and Operational Highlights	PRICE SENSITIVE	26/05/23	402.9KB	Share
MSB	Third Quarter Results Presentation		26/05/23	1.76MB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	26/05/23	591.58KB	Share
MSB	Mesoblast Third Quarter Financial Results Webcast		24/05/23	114.98KB	Share
MSB	Becoming a substantial holder		03/05/23	842.89KB	Share
MSB	Change in substantial holding		03/05/23	245.59KB	Share
MSB	Cleansing Notice		01/05/23	232.25KB	Share
MSB	Application for quotation of securities - MSB		28/04/23	23.26KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	416.6KB	Share
MSB	Reinstatement to Official Quotation	PRICE SENSITIVE	26/04/23	86.01KB	Share
MSB	Proposed issue of securities - MSB		26/04/23	24.49KB	Share
MSB	Mesoblast Completes Private Placement	PRICE SENSITIVE	26/04/23	169.21KB	Share
MSB	Voluntary Suspension	PRICE SENSITIVE	24/04/23	281.47KB	Share
MSB	Trading Halt	PRICE SENSITIVE	20/04/23	281.84KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	20/04/23	115.82KB	Share
MSB	FDA Schedules GvHD Pre-License Manufacturing Inspection		22/03/23	187.07KB	Share
MSB	Appendix 3G and Appendix 3H		15/03/23	652.68KB	Share
MSB	FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L	PRICE SENSITIVE	08/03/23	195.02KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	08/03/23	114.29KB	Share
MSB	Prospectus for Warrants Related to Oaktree Facility		03/03/23	509.39KB	Share
MSB	DREAM HF Trial Published in JACC	PRICE SENSITIVE	28/02/23	226.95KB	Share
MSB	MSB Q2 Financial Results and Operational Highlights	PRICE SENSITIVE	28/02/23	408.95KB	Share
MSB	Second Quarter Results Presentation		28/02/23	1.57MB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.67MB	Share
MSB	Mesoblast Second Quarter Financial Results Webcast		27/02/23	115.2KB	Share
MSB	Remestemcel Clinical and Potency Studies Presented at Tandem		17/02/23	175.63KB	Share
MSB	FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP		09/02/23	187.83KB	Share
MSB	Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD	PRICE SENSITIVE	01/02/23	195.59KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	419.11KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Ys		16/01/23	575.59KB	Share
MSB	Biotech Showcase 2023 Presentation in San Francisco		10/01/23	1.67MB	Share
MSB	Extension of Undrawn US$30 million Facility	PRICE SENSITIVE	23/12/22	161.36KB	Share
MSB	Proposed issue of securities - MSB		23/12/22	25.9KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Y		02/12/22	582.16KB	Share
MSB	Amended Constitution		24/11/22	626.04KB	Share
MSB	Results of Meeting		23/11/22	187.96KB	Share
MSB	Chairman's Address to Shareholders		23/11/22	192.3KB	Share
MSB	Long-Term Survival for Acute GvHD Treatment with Remestemcel	PRICE SENSITIVE	23/11/22	189.85KB	Share
MSB	MSB Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	23/11/22	439.61KB	Share
MSB	CEO First Quarter Results and 2022 AGM Presentation		23/11/22	2.06MB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	23/11/22	500.21KB	Share
MSB	Mesoblast First Quarter Financial Results Webcast		21/11/22	113.78KB	Share
MSB	Removal of Amendment to Constitution About Virtual Meetings		15/11/22	123.99KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	419.32KB	Share
MSB	Notice of Annual General Meeting and Proxy Form		24/10/22	443.56KB	Share
MSB	Annual Report to Shareholders		24/10/22	6.59MB	Share
MSB	Appendix 4G and Corporate Governance Statement		24/10/22	412.08KB	Share
MSB	Notification of cessation of securities - MSB		14/10/22	21.69KB	Share
MSB	Submits New Information to FDA IND File for SR-aGVHD	PRICE SENSITIVE	03/10/22	168.87KB	Share
MSB	Change of Director's Interest Notice		20/09/22	229.59KB	Share
MSB	Change of Director's Interest Notice		12/09/22	226.98KB	Share
MSB	MSB Annual Financial Results and Operational Highlights	PRICE SENSITIVE	31/08/22	386.1KB	Share
MSB	Annual Financial Results Presentation		31/08/22	1.83MB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	31/08/22	3.16MB	Share
MSB	Mesoblast 2022 Full Year Financial Results Webcast		30/08/22	116.05KB	Share
MSB	Director Appointment		18/08/22	133.74KB	Share
MSB	Initial Director's Interest Notice		18/08/22	305.67KB	Share
MSB	Final Director's Interest Notice		18/08/22	220.39KB	Share
MSB	Ceasing to be a substantial holder - Tiga Trading Pty Ltd		16/08/22	306.57KB	Share
MSB	Ceasing to be a substantial holder from TEK		16/08/22	324.86KB	Share
MSB	Ceasing to be a substantial holder from TOP		16/08/22	320.64KB	Share
MSB	Change in substantial holding		16/08/22	491.21KB	Share
MSB	Cleansing Notice		12/08/22	176.58KB	Share
MSB	Appendix 2A		12/08/22	357.17KB	Share
MSB	Appendix 3B		09/08/22	652.66KB	Share
MSB	US$45 Million Private Placement to Major Shareholders	PRICE SENSITIVE	09/08/22	157.61KB	Share
MSB	Reinstatement to Quotation	PRICE SENSITIVE	09/08/22	85.62KB	Share
MSB	Voluntary Suspension	PRICE SENSITIVE	08/08/22	221.75KB	Share
MSB	Trading Halt	PRICE SENSITIVE	04/08/22	206.88KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	04/08/22	116.13KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	444.42KB	Share
MSB	Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE	PRICE SENSITIVE	19/07/22	185.89KB	Share
MSB	Appendix 3H and Appendix 3Y		14/07/22	350.16KB	Share
MSB	Rexlemestrocel-L to be Highlighted on Heart Failure Panel		12/07/22	167.56KB	Share
MSB	Mesoblast CLBP Event with Key Opinion Leaders		21/06/22	168.79KB	Share
MSB	Chronic Low Back Pain KOL Event Presentation		21/06/22	6.92MB	Share
MSB	Litigation Update		14/06/22	172.01KB	Share

MSB Notification of cessation of securities - MSB
16/10/23		22.14KB	Share
MSB Notification regarding unquoted securities - MSB
16/10/23		25.52KB	Share
MSB Final Director's Interest Notice
29/09/23		289.13KB	Share
MSB Jane Bell Appointed Chair of Audit and Risk Committee
26/09/23		133KB	Share
MSB Mesoblast Type A Meeting with FDA
21/09/23		180.71KB	Share
MSB MSB Annual Financial Results and Operational Update
31/08/23	PRICE SENSITIVE	430.53KB	Share
MSB Annual Financial Results Presentation
31/08/23		1.55MB	Share
MSB Preliminary Final Report including Appendix 4E
31/08/23	PRICE SENSITIVE	2.9MB	Share
MSB Mesoblast 2023 Full Year Financial Results Webcast
29/08/23		113.86KB	Share
MSB Change in substantial holding
29/08/23		982.31KB	Share
MSB Ceasing to be a substantial holder
11/08/23		386.68KB	Share
MSB Ceasing to be a substantial holder
10/08/23		382.31KB	Share
MSB Change in substantial holding
10/08/23		477.4KB	Share
MSB Change in substantial holding
09/08/23		463.15KB	Share
MSB Change in substantial holding
09/08/23		481.52KB	Share
MSB Update on BLA for Graft Versus Host Disease
04/08/23	PRICE SENSITIVE	178.56KB	Share
MSB Change in substantial holding
03/08/23		560.83KB	Share
MSB Trading Halt
02/08/23	PRICE SENSITIVE	195.14KB	Share
MSB Change in substantial holding
01/08/23		538.92KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	401.67KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Ys
07/07/23		566.38KB	Share
MSB Change of Director's Interest Notice
13/06/23		259.12KB	Share
MSB Mesoblast Director Appointed to Strategic Advisory Role
05/06/23		161.1KB	Share
MSB MSB Reports Q3 Financial Results and Operational Highlights
26/05/23	PRICE SENSITIVE	402.9KB	Share
MSB Third Quarter Results Presentation
26/05/23		1.76MB	Share
MSB Third Quarter Financial Results on Form 6-K
26/05/23	PRICE SENSITIVE	591.58KB	Share
MSB Mesoblast Third Quarter Financial Results Webcast
24/05/23		114.98KB	Share
MSB Becoming a substantial holder
03/05/23		842.89KB	Share
MSB Change in substantial holding
03/05/23		245.59KB	Share
MSB Cleansing Notice
01/05/23		232.25KB	Share
MSB Application for quotation of securities - MSB
28/04/23		23.26KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	416.6KB	Share
MSB Reinstatement to Official Quotation
26/04/23	PRICE SENSITIVE	86.01KB	Share
MSB Proposed issue of securities - MSB
26/04/23		24.49KB	Share
MSB Mesoblast Completes Private Placement
26/04/23	PRICE SENSITIVE	169.21KB	Share
MSB Voluntary Suspension
24/04/23	PRICE SENSITIVE	281.47KB	Share
MSB Trading Halt
20/04/23	PRICE SENSITIVE	281.84KB	Share
MSB Pause in Trading
20/04/23	PRICE SENSITIVE	115.82KB	Share
MSB FDA Schedules GvHD Pre-License Manufacturing Inspection
22/03/23		187.07KB	Share
MSB Appendix 3G and Appendix 3H
15/03/23		652.68KB	Share
MSB FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
08/03/23	PRICE SENSITIVE	195.02KB	Share
MSB Pause in Trading
08/03/23	PRICE SENSITIVE	114.29KB	Share
MSB Prospectus for Warrants Related to Oaktree Facility
03/03/23		509.39KB	Share
MSB DREAM HF Trial Published in JACC
28/02/23	PRICE SENSITIVE	226.95KB	Share
MSB MSB Q2 Financial Results and Operational Highlights
28/02/23	PRICE SENSITIVE	408.95KB	Share
MSB Second Quarter Results Presentation
28/02/23		1.57MB	Share
MSB Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.67MB	Share
MSB Mesoblast Second Quarter Financial Results Webcast
27/02/23		115.2KB	Share
MSB Remestemcel Clinical and Potency Studies Presented at Tandem
17/02/23		175.63KB	Share
MSB FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP
09/02/23		187.83KB	Share
MSB Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
01/02/23	PRICE SENSITIVE	195.59KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	419.11KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Ys
16/01/23		575.59KB	Share
MSB Biotech Showcase 2023 Presentation in San Francisco
10/01/23		1.67MB	Share
MSB Extension of Undrawn US$30 million Facility
23/12/22	PRICE SENSITIVE	161.36KB	Share
MSB Proposed issue of securities - MSB
23/12/22		25.9KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Y
02/12/22		582.16KB	Share
MSB Amended Constitution
24/11/22		626.04KB	Share
MSB Results of Meeting
23/11/22		187.96KB	Share
MSB Chairman's Address to Shareholders
23/11/22		192.3KB	Share
MSB Long-Term Survival for Acute GvHD Treatment with Remestemcel
23/11/22	PRICE SENSITIVE	189.85KB	Share
MSB MSB Q1 Financial Results and Operational Highlights
23/11/22	PRICE SENSITIVE	439.61KB	Share
MSB CEO First Quarter Results and 2022 AGM Presentation
23/11/22		2.06MB	Share
MSB First Quarter Financial Results on Form 6-K
23/11/22	PRICE SENSITIVE	500.21KB	Share
MSB Mesoblast First Quarter Financial Results Webcast
21/11/22		113.78KB	Share
MSB Removal of Amendment to Constitution About Virtual Meetings
15/11/22		123.99KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	419.32KB	Share
MSB Notice of Annual General Meeting and Proxy Form
24/10/22		443.56KB	Share
MSB Annual Report to Shareholders
24/10/22		6.59MB	Share
MSB Appendix 4G and Corporate Governance Statement
24/10/22		412.08KB	Share
MSB Notification of cessation of securities - MSB
14/10/22		21.69KB	Share
MSB Submits New Information to FDA IND File for SR-aGVHD
03/10/22	PRICE SENSITIVE	168.87KB	Share
MSB Change of Director's Interest Notice
20/09/22		229.59KB	Share
MSB Change of Director's Interest Notice
12/09/22		226.98KB	Share
MSB MSB Annual Financial Results and Operational Highlights
31/08/22	PRICE SENSITIVE	386.1KB	Share
MSB Annual Financial Results Presentation
31/08/22		1.83MB	Share
MSB Preliminary Final Report
31/08/22	PRICE SENSITIVE	3.16MB	Share
MSB Mesoblast 2022 Full Year Financial Results Webcast
30/08/22		116.05KB	Share
MSB Director Appointment
18/08/22		133.74KB	Share
MSB Initial Director's Interest Notice
18/08/22		305.67KB	Share
MSB Final Director's Interest Notice
18/08/22		220.39KB	Share
MSB Ceasing to be a substantial holder - Tiga Trading Pty Ltd
16/08/22		306.57KB	Share
MSB Ceasing to be a substantial holder from TEK
16/08/22		324.86KB	Share
MSB Ceasing to be a substantial holder from TOP
16/08/22		320.64KB	Share
MSB Change in substantial holding
16/08/22		491.21KB	Share
MSB Cleansing Notice
12/08/22		176.58KB	Share
MSB Appendix 2A
12/08/22		357.17KB	Share
MSB Appendix 3B
09/08/22		652.66KB	Share
MSB US$45 Million Private Placement to Major Shareholders
09/08/22	PRICE SENSITIVE	157.61KB	Share
MSB Reinstatement to Quotation
09/08/22	PRICE SENSITIVE	85.62KB	Share
MSB Voluntary Suspension
08/08/22	PRICE SENSITIVE	221.75KB	Share
MSB Trading Halt
04/08/22	PRICE SENSITIVE	206.88KB	Share
MSB Pause in Trading
04/08/22	PRICE SENSITIVE	116.13KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	444.42KB	Share
MSB Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
19/07/22	PRICE SENSITIVE	185.89KB	Share
MSB Appendix 3H and Appendix 3Y
14/07/22		350.16KB	Share
MSB Rexlemestrocel-L to be Highlighted on Heart Failure Panel
12/07/22		167.56KB	Share
MSB Mesoblast CLBP Event with Key Opinion Leaders
21/06/22		168.79KB	Share
MSB Chronic Low Back Pain KOL Event Presentation
21/06/22		6.92MB	Share
MSB Litigation Update
14/06/22		172.01KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.29		Change 0.000(0.00%)		Mkt cap ! $2.931B

Open	High	Low	Value	Volume
$2.26	$2.31	$2.25	$4.493M	1.965M

Buyers (Bids)

No.	Vol.	Price($)
1	13044	$2.28

Sellers (Offers)

Price($)	Vol.	No.
$2.29	4885	3

View Market Depth

No.	Vol.	Price($)
1	13044	2.280
5	56371	2.270
7	81639	2.260
26	130952	2.250
11	25931	2.240

Price($)	Vol.	No.
2.290	4885	3
2.300	59567	4
2.310	15489	4
2.320	50600	3
2.330	23472	4

Last trade - 16.14pm 12/08/2025 (20 minute delay)


Last $2.28		Change 0.000 ( 0.33 %)
Open	High	Low	Volume
$2.27	$2.31	$2.26	689025
Last updated 15.59pm 12/08/2025 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories